logo-loader

ANGLE study results to be poster at major US cancer event

Published: 08:58 20 Apr 2015 BST

blood_cells350_5534b699bc67a

Medtech ANGLE (LON:AGL) said results from research at Sidney Kimmel Cancer Center using its Parsortix system will be postered at the upcoming American Association for Cancer Research annual meeting.

Sidney Kimmel tested Parsortix’s circulating tumour cell usefulness in single cell analysis for breast cancer. 

Dr Massimo Cristofanilli, the research director at Sidney Kimmel said:  "We demonstrated that using the Parsortix system in conjunction with DEPArray we are able to isolate single, uncontaminated tumor cells to achieve single cell molecular analysis.

“The use of single cells is emerging as a powerful approach to molecular analysis in oncology. 

“The Parsortix system has the ability to advance molecular testing, study cancer heterogeneity and apply concepts of precision medicine to breast cancer patients' care."  

Angle said there are major potential benefits if circulating tumour cells (CTCs) can be harvested from patient blood and then processed individually one-by-one as intact cells for analysis. 

"Technically this requires a high performance CTC capture and harvesting system that provides harvested CTCs in a form capable of then being processed by a single cell analysis system."

ANGLE chief executive, Andrew Newland, added; “Our aim is that the Parsortix system will provide a simple and effective way to harvest CTCs for mutation, gene expression and other types of molecular analysis so that there is a way to determine which drugs may benefit individual patients."

At Sidney Kimmel, Parsortix was used in combination with a DEPArray system to isolate single cancer cells from blood samples spiked with cultured breast cancer cells.  

The research proved the ability to manipulate the individual cancer cells from the Parsortix system and to correctly identify two breast cancer related genes (Estrogen receptor alpha (ESR1) and p53) on the cells using standard PCR analysis techniques.  

The work will now focus on molecular analysis in specified disease status. 


ANGLE PLC present at the Proactive One2One Investor Conference - January 11th

In a comprehensive presentation at the Proactive One2One Investor Conference, ANGLE PLC (AIM:AGL, OTCQX:ANPCY) CEO, Andrew Newland, and CFO, Ian Griffiths, detailed the company's innovative approach to cancer diagnosis and treatment. Newland emphasised ANGLE's breakthrough technology, the...

on 17/1/24